InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Abdomen-pelvis CT is the nation’s highest-volume CT category
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
The audit was completed with zero critical and zero major observations
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Subscribe To Our Newsletter & Stay Updated